"Summer Street believes that if approved, sales of MannKind's (MNKD) inhalable insulin Afrezza could be "substantially higher" than Pfizer’s (PFE) Exubera given Afrezza’s ease of use. However, the firm adds that it cannot accurately predict future sales of Afrezza at this time."
http://www.theflyonthewall.com/permalinks/entry.php/MNKD;PFEid1858409/MNKD;PFE-Afrezza-sales-could-be-higher-than-Exubera-says-Summer-Street